drugset
drugset / Trial / NCT01344876

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

NCT01344876 ↗

Phase 1 Completed 20 enrolled Otsuka Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the maximum tolerated dose (MTD) of OPB-51602

Timeline

Start
2011-04
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject OPB-51602 Unknown 1 mg Oral
Subject OPB-51602 Unknown 2 mg Oral
Subject OPB-51602 Unknown 4 mg Oral
Subject OPB-51602 Unknown 6 mg Oral

Indications

acute myeloid leukemia chronic myeloid leukemia lymphoid leukemia non-Hodgkin lymphoma plasma cell myeloma